305.61
price up icon2.59%   7.72
after-market 시간 외 거래: 309.00 3.39 +1.11%
loading
전일 마감가:
$297.89
열려 있는:
$304.67
하루 거래량:
223.38K
Relative Volume:
0.43
시가총액:
$13.79B
수익:
$2.99B
순이익/손실:
$1.21B
주가수익비율:
12.20
EPS:
25.06
순현금흐름:
$1.13B
1주 성능:
+2.50%
1개월 성능:
+6.71%
6개월 성능:
-17.82%
1년 성능:
-9.24%
1일 변동 폭
Value
$303.62
$306.92
1주일 범위
Value
$290.80
$306.92
52주 변동 폭
Value
$266.98
$417.81

유나이티드 테라퓨틱스 Stock (UTHR) Company Profile

Name
명칭
United Therapeutics Corp
Name
전화
(301) 608-9292
Name
주소
1000 SPRING ST, SILVER SPRING, MD
Name
직원
1,305
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
UTHR's Discussions on Twitter

UTHR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.61 13.44B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.45 67.31B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.74 45.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.75 43.35B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.58 18.68B 16.54B -1.64B 749.00M -1.45

유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-02 개시 Cantor Fitzgerald Overweight
2025-04-25 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-04-21 업그레이드 BofA Securities Underperform → Neutral
2024-07-11 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-02-12 업그레이드 Goldman Sell → Neutral
2024-02-05 개시 Leerink Partners Outperform
2023-12-08 개시 Wells Fargo Overweight
2022-12-06 개시 UBS Buy
2022-12-05 개시 Goldman Sell
2022-10-11 개시 Morgan Stanley Overweight
2022-09-20 재확인 BofA Securities Underperform
2022-09-19 재개 Wedbush Outperform
2022-02-11 개시 BTIG Research Neutral
2021-07-14 업그레이드 Argus Hold → Buy
2021-04-26 재개 Credit Suisse Outperform
2021-02-01 업그레이드 H.C. Wainwright Neutral → Buy
2020-09-14 재개 JP Morgan Overweight
2020-06-25 재확인 H.C. Wainwright Neutral
2020-03-10 업그레이드 Jefferies Hold → Buy
2020-02-27 업그레이드 Cowen Market Perform → Outperform
2020-01-31 업그레이드 JP Morgan Neutral → Overweight
2019-12-03 개시 BofA/Merrill Underperform
2019-08-01 업그레이드 Jefferies Underperform → Hold
2019-08-01 업그레이드 Ladenburg Thalmann Neutral → Buy
2019-07-01 업그레이드 Credit Suisse Neutral → Outperform
2019-05-17 업그레이드 UBS Sell → Neutral
2019-05-09 업그레이드 Credit Suisse Underperform → Neutral
2018-10-12 업그레이드 Standpoint Research Hold → Buy
2018-08-08 다운그레이드 Credit Suisse Neutral → Underperform
2018-04-03 업그레이드 Credit Suisse Underperform → Neutral
2018-02-22 재확인 Barclays Underweight
2018-01-18 재개 Credit Suisse Underperform
2017-12-27 재확인 Wedbush Outperform
2017-04-27 재확인 Wedbush Outperform
2017-03-30 개시 UBS Sell
2017-03-16 개시 Credit Suisse Underperform
모두보기

유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스

pulisher
Jul 21, 2025

United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

What analysts say about United Therapeutics Corporation stockConsistent triple returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Is United Therapeutics Corporation a good long term investmentBreakthrough profit margins - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

United Therapeutics Corporation Stock Analysis and ForecastAccelerated profit realization - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

What drives United Therapeutics Corporation stock priceSkyrocketing investment returns - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Here's Why United Therapeutics (UTHR) is a Strong Value Stock - Yahoo Finance

Jul 18, 2025
pulisher
Jul 17, 2025

Pulmonary Arterial Hypertension Market Forecast 2034: - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Jul 17, 2025
pulisher
Jul 17, 2025

Pulmonary Arterial Hypertension Drug Market Forecast to 2032: - openPR.com

Jul 17, 2025
pulisher
Jul 16, 2025

United Therapeutics Announces Q2 Earnings Date: Key Details for Biotech Investment Community - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest - Yahoo Finance

Jul 16, 2025
pulisher
Jul 15, 2025

Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $510 - 富途牛牛

Jul 15, 2025
pulisher
Jul 15, 2025

Reflecting On Therapeutics Stocks' Q1 Earnings: Moderna (NASDAQ:MRNA) - FinancialContent

Jul 15, 2025
pulisher
Jul 15, 2025

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

United Therapeutics Puts Big Bets On Tyvaso’s Trial Results - Finimize

Jul 14, 2025
pulisher
Jul 14, 2025

United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

United Therapeutics (UTHR) Awaits Key Catalyst with Positive Ris - GuruFocus

Jul 14, 2025
pulisher
Jul 14, 2025

United Therapeutic's: The Brands First Hydrogen Helicopter - Energy Digital Magazine

Jul 14, 2025
pulisher
Jul 11, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors - TipRanks

Jul 11, 2025
pulisher
Jul 10, 2025

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - Insider Monkey

Jul 10, 2025
pulisher
Jul 10, 2025

United Therapeutics (UTHR) Price Target Adjustment by Morgan Sta - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

United Therapeutics (UTHR) Price Target Trimmed by Morgan Stanle - GuruFocus

Jul 10, 2025
pulisher
Jul 09, 2025

United Therapeutics' Inhaled Treprostinil Study for Pulmonary Fibrosis: Key Insights for Investors - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

United Therapeutics (UTHR): JP Morgan Adjusts Price Target | UTH - GuruFocus

Jul 08, 2025
pulisher
Jul 04, 2025

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 04, 2025
pulisher
Jul 01, 2025

United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize

Jul 01, 2025
pulisher
Jun 30, 2025

United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lowered by UBS | UTHR Stock News - GuruFocus

Jun 30, 2025
pulisher
Jun 30, 2025

United Therapeutics’ Promising Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks

Jun 30, 2025
pulisher
Jun 30, 2025

United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lo - GuruFocus

Jun 30, 2025
pulisher
Jun 28, 2025

United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study - Yahoo Finance

Jun 28, 2025
pulisher
Jun 27, 2025

United Therapeutics EVP Mahon sells $3.14 million in UTHR stock - Investing.com

Jun 27, 2025
pulisher
Jun 26, 2025

United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment - TipRanks

Jun 26, 2025
pulisher
Jun 25, 2025

Nilda Mesa, United Therapeutics director, sells $187k in stock - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

United Therapeutics (UTHR) Begins Groundbreaking Clinical Study with miroliverELAP | UTHR Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 23, 2025

Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com

Jun 23, 2025
pulisher
Jun 17, 2025

United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com

Jun 16, 2025
pulisher
Jun 15, 2025

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga

Jun 15, 2025
pulisher
Jun 13, 2025

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 13, 2025
pulisher
Jun 11, 2025

United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

United Therapeutics: Tanking On Rival's PAH DataI'd Consider Buying Stock (NASDAQ:UTHR) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 10, 2025

Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News

Jun 10, 2025
pulisher
Jun 10, 2025

Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset - Seeking Alpha

Jun 10, 2025
pulisher
Jun 06, 2025

Treprostinil Saga Continues - JD Supra

Jun 06, 2025

유나이티드 테라퓨틱스 (UTHR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$133.66
price up icon 0.69%
drug_manufacturers_specialty_generic RDY
$14.60
price up icon 1.32%
$9.37
price up icon 1.41%
$16.58
price up icon 1.78%
$15.02
price up icon 0.60%
자본화:     |  볼륨(24시간):